CStone Pharmaceuticals
HKEX:2616

Watchlist Manager
CStone Pharmaceuticals Logo
CStone Pharmaceuticals
HKEX:2616
Watchlist
Price: 1.96 HKD -1.51% Market Closed
Market Cap: 2.5B HKD
Have any thoughts about
CStone Pharmaceuticals?
Write Note

CStone Pharmaceuticals
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CStone Pharmaceuticals
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
CStone Pharmaceuticals
HKEX:2616
Additional Paid In Capital
ÂĄ9B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Additional Paid In Capital
ÂĄ81.4B
CAGR 3-Years
15%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Additional Paid In Capital
ÂĄ3.3B
CAGR 3-Years
95%
CAGR 5-Years
81%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Additional Paid In Capital
ÂĄ13.8B
CAGR 3-Years
-2%
CAGR 5-Years
35%
CAGR 10-Years
20%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Additional Paid In Capital
ÂĄ3.5B
CAGR 3-Years
-1%
CAGR 5-Years
90%
CAGR 10-Years
N/A
No Stocks Found

CStone Pharmaceuticals
Glance View

Market Cap
2.5B HKD
Industry
Biotechnology

Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.

Intrinsic Value
3.12 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is CStone Pharmaceuticals's Additional Paid In Capital?
Additional Paid In Capital
9B CNY

Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Additional Paid In Capital amounts to 9B CNY.

What is CStone Pharmaceuticals's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
6%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for CStone Pharmaceuticals have been 2% over the past three years , 6% over the past five years .

Back to Top